Nav: Home

Hodgkin lymphoma survivors at high risk of second cancers

March 13, 2017

Patients who are cured of Hodgkin lymphoma are at a high risk of developing a second type of cancer, particularly if they have a family history of the disease, a major new study reports.

People who survived Hodgkin lymphoma were 2.4 times more likely to develop a second cancer of any type compared with people the same age and sex in the general population - and this risk remained high 30 years after treatment.

But the risk was even greater in people who were treated for Hodgkin lymphoma and had a family history of those specific cancers.

Scientists found that patients treated for Hodgkin lymphoma were 3 and a half times more likely to develop lung cancer if they had a close relative with lung cancer when compared to those without.

And those with a family history of breast or bowel cancer had around a two-fold increased risk of developing that cancer themselves.

The findings could help doctors identify patients most at risk of second cancers who might benefit from new risk-adapted treatment strategies, currently being evaluated in clinical trials, or increased monitoring for signs of specific second cancers.

Scientists at The Institute of Cancer Research, London, along with researchers in Sweden and Germany, analysed data from 9,522 patients with Hodgkin lymphoma and 28,277 relatives of the patients.

The study is published in the prestigious Journal of Clinical Oncology today (Monday), and is funded by Cancer Research UK, German Cancer Aid and the Swedish Research Council.

Some 30 per cent of people who had Hodgkin lymphoma in the study had one or more first-degree relatives with cancer.

Those with a family history of cancer were 2.8 times more likely to get a second cancer compared with 2.2 times more likely in patients with no first-degree relatives with cancer. People with two or more first-degree relatives with cancer were 3.4 times more likely to develop a second cancer.

The most common second cancers were non-Hodgkin lymphoma, leukaemia and lung, breast, bowel and non-melanoma skin cancers.

The researchers also found that increased risk of second cancer was linked to the age at diagnosis for both women and men.

Women diagnosed with Hodgkin lymphoma under the age of 35 had a 14 per cent risk of developing breast cancer over the next 30 years, whereas for those over 35 at diagnosis the risk was only 3 per cent.

Study author Dr Amit Sud, Clinical Research Fellow at The Institute of Cancer Research, London, said:

"The vast majority of patients with Hodgkin lymphoma are cured with a combination of chemotherapy and radiotherapy. Our research has shown that these patients are at substantially increased risk of a second cancer later in life - and particularly if they have a family history of cancer.

"Younger women who have been treated with radiotherapy to the chest for Hodgkin lymphoma are already screened for breast cancer, but our study suggests that we should be looking at ways of monitoring survivors for other forms of cancer too, and potentially offering preventative interventions.

"After patients are cured, they no longer encounter oncologists, so it's important that other healthcare providers are aware of the increased risk to Hodgkin lymphoma survivors to improve early diagnosis of second cancers."

Professor Richard Houlston, Professor of Molecular and Population Genetics at The Institute of Cancer Research, London, said:

"As cure rates for cancer improve, we are increasingly thinking about the long-term health of survivors, and how we can personalise the care they receive to take into account their own individual risks.

"This major new study has tracked the health of people who have survived Hodgkin lymphoma over several decades in order to provide a comprehensive assessment of the long-term risk of cancer. The research gives us invaluable information which we can look to use to tailor monitoring, screening or preventative treatment."

Martin Ledwick, Cancer Research UK's head cancer information nurse, said:

"People with Hodgkin's lymphoma are at a greater risk of developing a second cancer, particularly in those who were treated with radiotherapy approach that was used a few decades ago. A family history of breast cancer adds to their risk. This study is the first to show that a family history of lung and bowel cancer also play a role.

"The research shows that a family history of lung cancer carries the highest risk, and as the risk hasn't decreased as treatment has changed to use less radiotherapy, there may be factors other than heredity, such as family smoking habits, that are influencing the risk."
-end-
Notes to editors

For more information contact Ben Kolb on 020 7153 5359 or ben.kolb@icr.ac.uk. For enquiries out of hours, please call 07595 963 613.

The Institute of Cancer Research, London, is one of the world's most influential cancer research organisations.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four centres for cancer research and treatment globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

A college of the University of London, the ICR is the UK's top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

Institute of Cancer Research

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
One-third of breast cancer patients not getting appropriate breast imaging follow-up exam
An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
Low breast density worsens prognosis in breast cancer
Even though dense breast tissue is a risk factor for breast cancer, very low mammographic breast density is associated with a worse prognosis in breast cancer patients.
Is breast conserving therapy or mastectomy better for early breast cancer?
Young women with early breast cancer face a difficult choice about whether to opt for a mastectomy or breast conserving therapy (BCT).
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A.
Full dose radiotherapy to whole breast may not be needed in early breast cancer
Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with fewer side effects, researchers from the UK have found in the large IMPORT LOW trial.

Related Breast Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Setbacks
Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".